ALCHEMIA AWAITS APPROVAL

Written on the 6 April 2011

ALCHEMIA AWAITS APPROVAL

CONTINUING progress with its programs has not eased shareholder frustration with drug developer Alchemia due delays by the US Food and Drug Administration (FDA) to approve its new antithrombotic fondaparinux.

The company posted a net loss after tax of $6.7 million for the December half, with total income for the period of $784 000.

Managing director Pete Smith (pictured) says the company is working on other projects as it awaits approval of the injectible version of fondaparinux.

“We signed a partnership with US-based Emisphere Technologies to develop an oral formulation of the compound utilizing Eligen technology,” he says.

“This broad based drug delivery platform is designed to enhance the oral bioavailability of the drug without altering its chemical form or biological activity. An oral formulation of fondaparinux will expand the profile of the drug and potentially increase its market potential.”

The company has been preparing for the Phase 3 trial design for HA-Irinotecan, which will be initiated after approval for fondaparinux.

“The $25 million trial will be conducted in 60 sites in at least six countries and in July 2010 was adopted by the National Cancer Research network in the UK,” says Smith.

“This organisation provides the National Health Service in England, with the infrastructure to support cancer clinical trials and works closely with the cancer centers to provide clinical trial support across the UK.”

Over the past 12 months, the company has also spent significant time advancing its oncology platform, featuring HyACT tumor targeting technology.

TOP PUBLIC COMPANIES PROFILE: No. 39 Alchemia (ACL)

Managing director: Dr Pete Smith
Market Cap: $143 million
Revenue ’10: $629 000
Loss ’10: $8.8 million
Staff: 12
Established: 1995


Latest News

ADELAIDE APARTMENT BREAKS OFF-THE-PLAN RECORD WITH $3M SALE

AN apartment in 'The Adelaidean' residential development in Adelaide has sold for more than $3 million, which...

CABCHARGE GIVEN GREEN LIGHT TO BUY YELLOW CABS IN QUEENSLAND FOR $20M

THE consumer watchdog will not oppose the proposed acquisition of Yellow Cabs in Queensland by taxi payment service C...

SLEEPING ROUGH IN THE NAME OF CHARITY: 170 BRISBANE BUSINESS LEADERS TAKE PART IN THE CEO SLEEPOUT

OVER 170 Brisbane CEOs and business leaders will brave the cold tonight to fight homelessness in what will be the big...

DOMESTIC TOURISM IN AUSTRALIA BREAKS RECORDS, INJECTS $61.7 BILLION INTO NATIONAL ECONOMY

DOMESTIC Australian tourists have spent a record breaking $61.7 billion on intra and interstate travel this year, acc...

Related News

DOMESTIC TOURISM IN AUSTRALIA BREAKS RECORDS, INJECTS $61.7 BILLION INTO NATIONAL ECONOMY

DOMESTIC Australian tourists have spent a record breaking $61.7 billion on intra and interstate travel this year, acc...

THE DOCTORS WHO PLUNGED INTO THE SHARK TANK AND SURVIVED WITH A $500,000 INVESTMENT

THEIR mission is to change the face of cancer care with an app that empowers and connects patients and care givers...

IMF BRACES FOR BIG LOSS FOLLOWING WITHDRAWAL FROM SPOTLESS CLASS ACTION

LITIGATION fund IMF Bentham (ASX: IMF) is set to lose as much as half a million dollars after it ceases funding one o...

WAGERING GIANTS TABCORP AND TATTS GIVEN GREEN LIGHT FOR $11B MERGER

THE Competition Tribunal has approved Tabcorp's (ASX: TAH) $11bn takeover bid for Tatts (ASX: TTS) on the conditi...

BOOK YOUR FUNCTION SPACE HERE

 

 

 

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter